维拉帕米对囊性纤维化相关血糖异常的影响

该数据集来自 clinicaltrials.gov,主题为维拉帕米在囊性纤维化相关血糖异常中的效应研究。覆盖囊性纤维化相关糖尿病、囊性纤维化及异常糖耐量等状况

Rhode Island HospitalRhode Island Hospital
clinicaltrials
浏览 10
蛋白质预测Cystic Fibrosis Related DiabetesCystic Fibrosis (CF)Abnormal Glucose Tolerance
Verapamil Effect in Cystic Fibrosis-related Dysglycemia

基本信息

模态
蛋白质
任务类型
预测
创建/更新时间
2026-10-12

资源简介

维拉帕米对囊性纤维化相关血糖异常的影响

该数据集来自 clinicaltrials.gov,主题为维拉帕米在囊性纤维化相关血糖异常中的效应研究。覆盖囊性纤维化相关糖尿病、囊性纤维化及异常糖耐量等状况。囊性纤维化相关糖尿病是 CF 常见非肺部并发症,与肺功能下降、营养状况恶化、更早死亡及生活质量受损相关;血糖异常通常始于异常糖耐量,表现为第一时相胰岛素分泌受损和餐后高血糖,并可进展为 CFRD。目前胰岛素是唯一推荐疗法,尚无针对 β 细胞功能障碍或阻止 AGT 进展的获批疗法。该数据可用于相关预测研究(来源 clinicaltrials.gov)。

【数据内容】

源站描述(机器翻译,仅供参考):状况:囊性纤维化相关糖尿病、囊性纤维化(CF)、异常糖耐量。囊性纤维化相关糖尿病(CFRD)是囊性纤维化(CF)最常见的非肺部并发症之一,与肺功能下降、营养状况恶化、更早死亡及生活质量受损相关。CF 中的血糖异常通常始于异常糖耐量(AGT),其特征为第一时相胰岛素分泌受损和餐后高血糖,并可能随时间进展为 CFRD。胰岛素治疗目前是 CFRD 唯一推荐的治疗方法;然而,它给本已医疗复杂的人群增加了沉重的治疗负担。目前,尚无针对 β 细胞功能障碍或旨在预防 CF 患者从 AGT 进展为 CFRD 的获批疗法。CFRD 的病理生理学正日益被认识到

【主题与分类】

主题标签:Cystic Fibrosis Related Diabetes、Cystic Fibrosis (CF)、Abnormal Glucose Tolerance。本站分类:循环系统疾病/其他。

【获取与许可】

源站页面:https://clinicaltrials.gov/study/NCT07688070

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付,我们提供全链路闭环服务,让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持?联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务(收技术服务费,非数据销售)

暂未开放

当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取

源站:https://clinicaltrials.gov/study/NCT07688070

标准获取流程:

  1. 访问源站链接,注册/登录账号;
  2. 进入数据集详情页,按页面指引申请权限或直接下载;
  3. 部分平台提供 SDK,例如:
    • OpenDataLab: pip install openxlab 后 openxlab.dataset.get(...)
    • ModelScope: pip install modelscope 后 modelscope download
    • 天池: 登录后页面提供直链下载
      以源站「数据下载/使用文档」页面为准。

数据说明

Conditions: Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance. Cystic fibrosis-related diabetes (CFRD) is one of the most common non-pulmonary complications of cystic fibrosis (CF) and is associated with reduced pulmonary function, worse nutritional status, earlier mortality, and impaired quality of life. Dysglycemia in CF typically begins with abnormal glucose tolerance (AGT), characterized by impaired first-phase insulin secretion and postprandial hyperglycemia, and may progress over time to CFRD. Insulin therapy is currently the only recommended treatment for CFRD; however, it adds substantial treatment burden to an already medically complex population. At present, there are no approved therapies targeting beta cell dysfunction or aimed at preventing progression from AGT to CFRD in people with CF. The pathophysiology of CFRD is increasingly recognized as being driven primarily by beta cell dysfunction rather than complete beta cell destruction. Although insulin secretion is impaired in CF, beta cell mass is relatively preserved compared with type 1 diabetes mellitus (T1D), and residual endogenous insulin production often persists for many years after CFRD diagnosis. Mechanisms contributing to beta cell dysfunction in CF are believed to include oxidative stress, inflammation, endoplasmic reticulum stress, impaired antioxidant defenses, and islet immune dysregulation. Thioredoxin-interacting protein (TXNIP), a key cellular regulator of oxidative stress, has been implicated in beta cell dysfunction and apoptosis in other forms of diabetes mellitus. Verapamil, a calcium channel blocker commonly used for hypertension and arrhythmias, has been shown to reduce TXNIP expression, decrease inflammatory signaling, and promote beta cell survival. Given the known role of oxidative stress in the CF pancreas and the preservation of residual beta cell function in CFRD, verapamil represents a promising candidate therapy for modifying beta cell dysfunction and improving dysglycemia in CF. However, the effects of verapamil on beta cell functio

数据加载示例(图像类)

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据缺失?

依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。

⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。

获取专属数据定制方案